2022
Clinical predictors of longer survival in patients with BRAF V600 -mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting.
Kahn A, Perry C, Etts K, Kluger H, Sznol M. Clinical predictors of longer survival in patients with BRAF V600 -mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting. Journal Of Clinical Oncology 2022, 40: 9555-9555. DOI: 10.1200/jco.2022.40.16_suppl.9555.Peer-Reviewed Original ResearchBRAF/MEKiFirst-line immunotherapyBRAF/MEK inhibitionBRAF V600Metastatic melanomaLonger survivalAdverse eventsMedian durationMost patientsBone metastasesClinical predictorsDisease progressionMEK inhibitionAdvanced BRAF V600ECOG PS 0Median ECOG PSFirst-line settingKaplan-Meier methodMost common sitePredictors of survivalECOG PSMedian LDHData cutoffMetastatic settingMedian survival
2020
Systemic Therapy for Brain Metastases: Melanoma
Weiss S, Kluger H. Systemic Therapy for Brain Metastases: Melanoma. 2020, 235-244. DOI: 10.1007/978-3-030-42958-4_16.Peer-Reviewed Original ResearchMelanoma brain metastasesIntracranial response ratesBrain metastasesClinical trialsResponse rateAnti-PD-1 monotherapyCentral nervous system metastasesExtracranial metastatic sitesNervous system metastasesSystemic therapy approachesMultiple clinical trialsSystemic therapySystemic treatmentAdvanced melanomaImmune checkpointsMetastatic sitesTherapeutic challengePatient survivalMetastatic melanomaExtracranial sitesStereotactic radiosurgeryMetastasisMutant BRAFSignificant causeMEK inhibition